Single-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors.
作者信息
Koumprentziotis Ioannis-Alexios, Rompoti Natalia, Stefanaki Irene, Vavouli Charitomeni, Politou Maria, Papoutsaki Marina, Stratigos Alexander, Nicolaidou Electra
机构信息
1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
出版信息
Int J Dermatol. 2025 Jun;64(6):1092-1094. doi: 10.1111/ijd.17630. Epub 2024 Dec 30.
Abstract
摘要
相似文献
1
Single-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors.在先前接触过白细胞介素-17抑制剂的银屑病患者中使用比美吉珠单抗的单中心经验。
Int J Dermatol. 2025 Jun;64(6):1092-1094. doi: 10.1111/ijd.17630. Epub 2024 Dec 30.
2
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.中度至重度斑块状银屑病患者的比美吉珠单抗治疗：药物安全性评估
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):355-362. doi: 10.1080/14740338.2023.2218086. Epub 2023 Jun 19.
3
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review.
J Am Acad Dermatol. 2025 May;92(5):1093-1095. doi: 10.1016/j.jaad.2024.12.034. Epub 2025 Jan 20.
4
Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review.用于治疗斑块状银屑病的比美吉珠单抗-bkzx：药物综述
Ann Pharmacother. 2025 Jun;59(6):577-584. doi: 10.1177/10600280241288553. Epub 2024 Oct 19.
5
Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review".
J Am Acad Dermatol. 2025 Jun;92(6):e191-e193. doi: 10.1016/j.jaad.2024.11.083. Epub 2025 Feb 14.
6
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.比美吉珠单抗及其他生物制剂治疗中度至重度斑块状银屑病的疗效：系统文献综述与网状Meta分析
Dermatol Ther (Heidelb). 2022 Aug;12(8):1777-1792. doi: 10.1007/s13555-022-00760-8. Epub 2022 Jul 7.
7
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
8
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.比美替尼：一种用于治疗银屑病和银屑病关节炎的双重 IL-17A 和 IL-17F 抑制剂。
Expert Rev Clin Immunol. 2021 Oct;17(10):1073-1081. doi: 10.1080/1744666X.2021.1967748. Epub 2021 Aug 20.
9
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience.用于治疗斑块状银屑病的白细胞介素-17抑制剂类间的换药：单中心经验
Dermatol Reports. 2024 Nov 12. doi: 10.4081/dr.2024.10080.
10
Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.真实世界中比美吉珠单抗治疗日本银屑病患者的疗效和安全性：一项单中心回顾性研究。
J Dermatol. 2024 May;51(5):649-658. doi: 10.1111/1346-8138.17186. Epub 2024 Mar 14.
引用本文的文献
1
Bimekizumab for Psoriasis: Raising the Bar in Treatment.用于治疗银屑病的比美吉珠单抗：提升治疗标准。
Int J Dermatol. 2025 Jun;64(6):969-970. doi: 10.1111/ijd.17736. Epub 2025 Mar 21.
本文引用的文献
1
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.在既往使用过白细胞介素-17抑制剂的成年斑块状银屑病患者中使用比美吉珠单抗的真实世界经验：一项为期16周的多中心回顾性研究。
J Am Acad Dermatol. 2024 Dec;91(6):1265-1267. doi: 10.1016/j.jaad.2024.07.1515. Epub 2024 Aug 23.
2
Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.比美吉珠单抗治疗银屑病：一项真实世界环境下评估短期和中期疗效及安全性的单中心研究。
Arch Dermatol Res. 2024 Apr 25;316(5):133. doi: 10.1007/s00403-024-02868-7.
3
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.在从阿达木单抗、乌司奴单抗或司库奇尤单抗转换治疗的中重度斑块型银屑病患者中，比美吉珠单抗的疗效和安全性：III 期/IIIb 期试验结果。
Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089.
4
Bimekizumab versus Secukinumab in Plaque Psoriasis.比美吉珠单抗与司库奇尤单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
5
Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis.银屑病患者中第二种白细胞介素 17 抑制剂的疗效：系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):130-138. doi: 10.1016/j.jaad.2020.07.085. Epub 2020 Jul 28.
Zotero 插件